vs
Orthofix Medical Inc.（OFIX）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是STURM RUGER & CO INC的1.5倍（$219.9M vs $151.1M），STURM RUGER & CO INC同比增速更快（3.6% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $12.3M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 5.1%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
OFIX vs RGR — 直观对比
营收规模更大
OFIX
是对方的1.5倍
$151.1M
营收增速更快
RGR
高出1.7%
2.0%
自由现金流更多
OFIX
多$4.5M
$12.3M
两年增速更快
OFIX
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $151.1M |
| 净利润 | $-2.2M | — |
| 毛利率 | 71.1% | 17.8% |
| 营业利润率 | 0.2% | 2.3% |
| 净利率 | -1.0% | — |
| 营收同比 | 2.0% | 3.6% |
| 净利润同比 | 92.4% | — |
| 每股收益（稀释后） | $-0.05 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRGR
| Q4 25 | $219.9M | $151.1M | ||
| Q3 25 | $205.6M | $126.8M | ||
| Q2 25 | $203.1M | $132.5M | ||
| Q1 25 | $193.6M | $135.7M | ||
| Q4 24 | $215.7M | $145.8M | ||
| Q3 24 | $196.6M | $122.3M | ||
| Q2 24 | $198.6M | $130.8M | ||
| Q1 24 | $188.6M | $136.8M |
净利润OFIXRGR
| Q4 25 | $-2.2M | — | ||
| Q3 25 | $-22.8M | $1.6M | ||
| Q2 25 | $-14.1M | $-17.2M | ||
| Q1 25 | $-53.1M | $7.8M | ||
| Q4 24 | $-29.1M | — | ||
| Q3 24 | $-27.4M | $4.7M | ||
| Q2 24 | $-33.4M | $8.3M | ||
| Q1 24 | $-36.0M | $7.1M |
毛利率OFIXRGR
| Q4 25 | 71.1% | 17.8% | ||
| Q3 25 | 72.2% | 15.1% | ||
| Q2 25 | 68.7% | 3.9% | ||
| Q1 25 | 62.8% | 22.0% | ||
| Q4 24 | 69.0% | 22.8% | ||
| Q3 24 | 68.7% | 18.5% | ||
| Q2 24 | 67.8% | 22.3% | ||
| Q1 24 | 67.5% | 21.5% |
营业利润率OFIXRGR
| Q4 25 | 0.2% | 2.3% | ||
| Q3 25 | -8.3% | -2.7% | ||
| Q2 25 | -7.9% | -15.6% | ||
| Q1 25 | -25.2% | 6.2% | ||
| Q4 24 | -5.3% | 7.8% | ||
| Q3 24 | -9.6% | 3.1% | ||
| Q2 24 | -12.5% | 6.9% | ||
| Q1 24 | -15.6% | 5.5% |
净利率OFIXRGR
| Q4 25 | -1.0% | — | ||
| Q3 25 | -11.1% | 1.2% | ||
| Q2 25 | -6.9% | -13.0% | ||
| Q1 25 | -27.4% | 5.7% | ||
| Q4 24 | -13.5% | — | ||
| Q3 24 | -13.9% | 3.9% | ||
| Q2 24 | -16.8% | 6.3% | ||
| Q1 24 | -19.1% | 5.2% |
每股收益（稀释后）OFIXRGR
| Q4 25 | $-0.05 | $0.22 | ||
| Q3 25 | $-0.57 | $0.10 | ||
| Q2 25 | $-0.36 | $-1.05 | ||
| Q1 25 | $-1.35 | $0.46 | ||
| Q4 24 | $-0.76 | $0.62 | ||
| Q3 24 | $-0.71 | $0.28 | ||
| Q2 24 | $-0.88 | $0.47 | ||
| Q1 24 | $-0.95 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $283.8M |
| 总资产 | $850.6M | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXRGR
| Q4 25 | $82.0M | $92.5M | ||
| Q3 25 | $62.9M | $80.8M | ||
| Q2 25 | $65.6M | $101.4M | ||
| Q1 25 | $58.0M | $108.3M | ||
| Q4 24 | $83.2M | $105.5M | ||
| Q3 24 | $30.1M | $96.0M | ||
| Q2 24 | $26.4M | $105.6M | ||
| Q1 24 | $27.0M | $115.3M |
总债务OFIXRGR
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXRGR
| Q4 25 | $450.0M | $283.8M | ||
| Q3 25 | $442.5M | $279.6M | ||
| Q2 25 | $458.3M | $289.3M | ||
| Q1 25 | $458.3M | $321.5M | ||
| Q4 24 | $503.1M | $319.6M | ||
| Q3 24 | $525.9M | $314.9M | ||
| Q2 24 | $546.0M | $321.5M | ||
| Q1 24 | $570.3M | $332.0M |
总资产OFIXRGR
| Q4 25 | $850.6M | $342.0M | ||
| Q3 25 | $832.6M | $342.3M | ||
| Q2 25 | $837.2M | $349.5M | ||
| Q1 25 | $823.1M | $379.0M | ||
| Q4 24 | $893.3M | $384.0M | ||
| Q3 24 | $867.9M | $373.5M | ||
| Q2 24 | $882.0M | $376.7M | ||
| Q1 24 | $906.0M | $385.0M |
负债/权益比OFIXRGR
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $12.3M |
| 自由现金流率自由现金流/营收 | 7.6% | 8.2% |
| 资本支出强度资本支出/营收 | 4.9% | 2.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $38.5M |
8季度趋势，按日历期对齐
经营现金流OFIXRGR
| Q4 25 | $27.7M | $15.5M | ||
| Q3 25 | $12.4M | $12.9M | ||
| Q2 25 | $11.6M | $14.7M | ||
| Q1 25 | $-18.4M | $11.1M | ||
| Q4 24 | $23.7M | $20.0M | ||
| Q3 24 | $11.7M | $9.4M | ||
| Q2 24 | $9.0M | $18.7M | ||
| Q1 24 | $-18.6M | $7.3M |
自由现金流OFIXRGR
| Q4 25 | $16.8M | $12.3M | ||
| Q3 25 | $2.5M | $7.0M | ||
| Q2 25 | $4.5M | $9.1M | ||
| Q1 25 | $-25.1M | $10.0M | ||
| Q4 24 | $15.2M | $16.4M | ||
| Q3 24 | $6.3M | $2.6M | ||
| Q2 24 | $-360.0K | $10.1M | ||
| Q1 24 | $-29.1M | $5.6M |
自由现金流率OFIXRGR
| Q4 25 | 7.6% | 8.2% | ||
| Q3 25 | 1.2% | 5.5% | ||
| Q2 25 | 2.2% | 6.9% | ||
| Q1 25 | -13.0% | 7.4% | ||
| Q4 24 | 7.0% | 11.2% | ||
| Q3 24 | 3.2% | 2.1% | ||
| Q2 24 | -0.2% | 7.7% | ||
| Q1 24 | -15.4% | 4.1% |
资本支出强度OFIXRGR
| Q4 25 | 4.9% | 2.1% | ||
| Q3 25 | 4.8% | 4.6% | ||
| Q2 25 | 3.5% | 4.2% | ||
| Q1 25 | 3.5% | 0.8% | ||
| Q4 24 | 4.0% | 2.5% | ||
| Q3 24 | 2.7% | 5.5% | ||
| Q2 24 | 4.7% | 6.6% | ||
| Q1 24 | 5.6% | 1.3% |
现金转化率OFIXRGR
| Q4 25 | — | — | ||
| Q3 25 | — | 8.15× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | — | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
